KRAS G12C inhibitor 39
KRAS G12C inhibitor 39 is a potent inhibitor of KRAS G12C. KRas is a highly attractable target of the pharmaceutical industry for cancer research. KRAS G12C inhibitor 39 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2019099524A1, compound 494) [1].
Product Specifications
CAS Number
2326522-16-9
UNSPSC
12352005
Target
Ras
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/kras-g12c-inhibitor-39.html
Solubility
10 mM in DMSO
Smiles
N#CC[C@@H]1N(C(/C=C/C2=CN(C)N=C2)=O)CCN(C3=C4C(CN(C5=C6C(C)=CC=CC6=CC=C5)CC4)=NC(OC[C@H]7N(C)CCC7)=N3)C1
Molecular Formula
C37H43N9O2
Molecular Weight
645.80
References & Citations
[1]James F. Blake, et al. Kras g12c inhibitors. Patent WO2019099524A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TNF alpha (J2D10), CF647 conjugate, 0.1mg/mL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF568 conjugate, 0.1mg/mL
